Legal & General Group Plc Raises Holdings in Natera, Inc. $NTRA

Legal & General Group Plc raised its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 8.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 363,121 shares of the medical research company’s stock after purchasing an additional 27,136 shares during the period. Legal & General Group Plc’s holdings in Natera were worth $83,187,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Horizon Investments LLC raised its position in Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC raised its position in Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares during the last quarter. Savvy Advisors Inc. raised its position in Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares during the last quarter. Siemens Fonds Invest GmbH raised its position in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 54 shares during the last quarter. Finally, First Horizon Corp raised its position in Natera by 7.3% during the 4th quarter. First Horizon Corp now owns 931 shares of the medical research company’s stock valued at $213,000 after purchasing an additional 63 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 5,838 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $204.14, for a total transaction of $1,191,769.32. Following the completion of the transaction, the chief executive officer owned 150,769 shares of the company’s stock, valued at $30,777,983.66. This trade represents a 3.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 1,688 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $204.10, for a total value of $344,520.80. Following the transaction, the insider directly owned 187,511 shares of the company’s stock, valued at approximately $38,270,995.10. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 41,356 shares of company stock worth $8,374,584 over the last 90 days. 5.63% of the stock is currently owned by insiders.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $223.37 on Friday. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $256.36. The firm has a market capitalization of $31.99 billion, a P/E ratio of -137.04 and a beta of 1.57. The stock has a 50 day moving average price of $202.37 and a 200-day moving average price of $215.69.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The firm had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. During the same quarter in the prior year, the company earned ($0.41) EPS. On average, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of a number of recent analyst reports. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Evercore reaffirmed an “outperform” rating and set a $270.00 price target on shares of Natera in a research report on Friday, May 8th. Morgan Stanley lowered their price target on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. BTIG Research lowered their price target on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Finally, Robert W. Baird set a $265.00 price target on Natera in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $256.60.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.